Autopsy report · NCT04906811

Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

“Study discontinued due to lack of subject follow-up.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 9 months before it stopped.
• 17 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

AuraGen Aesthetics LLC

Sponsor type

Industry

Conditions

Autologous Fat Grafting

Interventions

AuraGen 1-2-3 with AuraClens system (BK190433); Revolve System (K120902)

Participants

17

Sites

1

Countries

United States

Trials that died the same way

• The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study
  “Study discontinued due to lack of study funding.” (86% match in meaning)
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
  “Study discontinued due to futility.” (85% match in meaning)
• Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence
  “Study discontinued due to low accrual.” (85% match in meaning)
• Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries
  “The study was discontinued early due to lack of funding and slow enrollment” (83% match in meaning)
• KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
  “Study discontinued due to sponsor decision.” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.